Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
Vertex Pharmaceuticals (VRTX) Stock Price & Analysis
5,135 Followers
VRTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$316.43 - $448.40
Previous Close$394.17
Volume133.70K
Average Volume (3M)1.25M
Market Cap
$102.91B
Enterprise Value$92.15B
Total Cash (Recent Filing)$11.22B
Total Debt (Recent Filing)$724.70M
Price to Earnings (P/E)28.4
Beta0.60
Next Earnings
May 06, 2024EPS Estimate
$4.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.89
Shares Outstanding258,307,816
10 Day Avg. Volume949,667
30 Day Avg. Volume1,246,798
Standard Deviation0.08
R-Squared0.06
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)6.55
Price to Sales (P/S)40.77
Price to Cash Flow (P/CF)109.20
P/FCF Ratio186.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.34
Enterprise Value/Gross Profit10.71
Enterprise Value/Ebitda27.23
Forecast
1Y Price Target
$458.22Price Target Upside15.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering26
Vertex Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentPovetacicept's potential for best-in-class status is strengthened by recent clinical data showing significant disease modification in IgA Nephropathy.
Financial OutlookAnalysts maintain an Outperform rating on Vertex, signaling confidence in the company's financial stability and strategic acquisitions.
Strategic AcquisitionThe acquisition of Alpine Immune Sciences is expected to enhance Vertex's nephrology pipeline and immunoinflammatory capabilities, indicating a solid strategic fit.
Bears Say
Drug DevelopmentDisappointing results in the bunionectomy trial versus the active opioid control could limit access for hard tissue pain treatment.
Drug EfficacySmall sample sizes with no placebo make extrapolation to effect size difficult.
Financial ValuationVertex shares are trading at a premium valuation compared to its mega-cap BioPharma peers.
---
Ownership Overview
1.07% Insiders
51.76% Mutual Funds
23.46% Other Institutional Investors
23.72% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRTX FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was $316.43 and its highest was $448.40 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Currently, no data Available
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is May 06, 2024 which is in 18 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on Feb 05, 2024. The company reported $4.2 earnings per share for the quarter, beating the consensus estimate of $4.067 by $0.133.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is $4.07.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 258,307,830 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of $4.2 in its last earnings report, beating expectations of $4.067. Following the earnings report the stock price went down -2.975%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Among the largest hedge funds holding Vertex Pharmaceuticals’s share is Bridgewater Associates, LP. It holds Vertex Pharmaceuticals’s shares valued at 54M.
---
Vertex Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$458.22 (15.95% Upside)
$458.22 (15.95% Upside)
Blogger Sentiment
Bullish
VRTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.18%
12-Months-Change
Fundamentals
Return on Equity
22.99%
Trailing 12-Months
Asset Growth
27.19%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
---
VRTX Company Deck
---
VRTX Earnings Call
Q4 2024
0:00 / 0:00
---
VRTX Revenue Breakdown
90.63% TRIKAFTA/KAFTRIO
4.82% KALYDECO
3.30% ORKAMBI
1.25% SYMDEKO/SYMKEVI
---
VRTX Stock 12 Months Forecast
Average Price Target
$458.22
▲(15.95% Upside)
Technical Analysis
Best Analysts Covering VRTX
1 Year
1 Year Success Rate
20/20 ratings generated profit
1 Year Average Return
+32.48%
reiterated a sell rating 8 days ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +32.48% per trade.
---